Sofinnova Investments’s Halozyme HALO Stock Holding History

Sofinnova Investments’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-72,481	Closed	-$1.28M	–	66
2019 Q4	$1.28M	Sell	72,481 -563,686	-89%	-$9.76M	0.09%	56
2019 Q3	$9.87M	Sell	636,167 -54,032	-8%	-$890K	0.89%	27
2019 Q2	$11.9M	Buy	690,199 +288,870	+72%	+$4.66M	1.09%	22
2019 Q1	$6.46M	Buy	+401,329	New	+$6.5M	0.62%	31

Other funds holding HALO

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Sofinnova Investments's HALO Position: Q1 2020 in Review

Sofinnova Investments sold out of Halozyme (HALO) in Q1 2020, closing a stake of 72,481 shares — an estimated $1.28M sold.

Sofinnova Investments first reported a position in HALO in Q1 2019 and held it in 4 quarters. The position peaked at $11.9M in Q2 2019. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2020.

Sofinnova Investments reported no remaining Halozyme position as of Q1 2020 after selling out during the quarter.
Sofinnova Investments sold 72,481 Halozyme shares in Q1 2020, an estimated $1.28M.
Sofinnova Investments first reported a position in Halozyme in Q1 2019 and held it in 4 quarters.
Sofinnova Investments's Halozyme position peaked at $11.9M in Q2 2019.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2020.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.